Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck' anti-PD-1 Keytruda fails as a monotherapy with chemo

<< Previous

Bullboard Posts

Next >>

Comment by fasttrack5on Aug 29, 2024 11:51am

90 Views

Post# 36201298

RE:RE:RE:Merck' anti-PD-1 Keytruda fails as a monotherapy with chemo

This been said.
ONCY's drug platfrom pelareorep "primes" the immune system and remodels the tumor microenvironment (TME) in advance of the addition of an immune checkpoint inhibitor, like Merck's Keytruda, resulting in the synergistic effectiveness in the combined effort of both pelareorep AND the immune checkpoint inhibitor in the treatment of cancer
When Will Merck take a look what's holding ten back???????

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing